Post-IPO Debt Funded Biotechnology Startups
Post-IPO Debt rounds recorded across these 50 biotech companies span March through October 2022 and range from Awakn Life Sciences' $570K raise in Toronto…
Post-IPO Debt rounds recorded across these 50 biotech companies span March through October 2022 and range from Awakn Life Sciences' $570K raise in Toronto to Medtronic's $3.5B transaction in Minneapolis. A substantial portion of transactions fall in the $20M–$200M band — illustrated by Elevation Oncology ($50M, New York), Adaptive Biotechnologies ($125M, Seattle), and Replimune Group ($200M, Woburn) — though several push considerably higher, including Alnylam Pharmaceuticals ($900M, Cambridge), Thermo Fisher Scientific ($741M, Waltham), and Cytokinetics ($450M, South San Francisco).
The United States dominates geographically, with Massachusetts producing nine entries — four from Cambridge alone (VBI Vaccines, Alnylam Pharmaceuticals, Akero Therapeutics, Oncorus) — and California contributing seven. Canada adds nine companies from Ontario, British Columbia, Quebec, and Alberta, making it the most active non-US country in the dataset. European issuers include BerGenBio in Bergen, ATAI Life Sciences in Munich, Verona Pharma in London, and Perrigo in Dublin, whose $2.6B raise is the second largest in the set.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest Post-IPO Debt rounds in this biotech dataset?
The top five by size are Medtronic ($3.5B, Minneapolis, September 2022), Perrigo ($2.6B, Dublin, April 2022), Alnylam Pharmaceuticals ($900M, Cambridge MA, September 2022), Thermo Fisher Scientific ($741M, Waltham, October 2022), and Cytokinetics ($450M, South San Francisco, July 2022). These five transactions alone account for a disproportionate share of total capital in the 50 rows shown.
Which US cities and states show the most concentration in this dataset?
Massachusetts leads with nine entries, four of them from Cambridge alone — VBI Vaccines, Alnylam Pharmaceuticals, Akero Therapeutics, and Oncorus — with the remaining five spread across Boston, Waltham, Woburn, Natick, and Needham. California follows with seven companies across San Jose, Irvine, Emeryville, South San Francisco, San Carlos, and Palo Alto. New Jersey contributes four: Insmed (Bridgewater), PDS Biotechnology (North Brunswick), IVERIC bio (Princeton), and ADMA Biologics (Ramsey).
How many non-US companies appear, and which countries are represented?
Canada has nine entries — the most of any non-US country — from Ontario, British Columbia, Quebec, and Alberta, including HLS Therapeutics (Caledon), Valeo Pharma (Kirkland), and Theratechnologies (Montréal). European issuers span nine countries: Norway (BerGenBio), Germany (ATAI Life Sciences), Switzerland (Kinarus Therapeutics, Sequana Medical), France (Inventiva Pharma, Valneva), the UK (Verona Pharma), Sweden (Brighter), and Ireland (Perrigo), plus Opthea in Australia and PolyPid in Israel.
Do smaller publicly traded biotech companies also use Post-IPO Debt, or is it mainly large-caps?
Both ends of the market appear. Sub-$10M raises include Awakn Life Sciences ($570K, Toronto), Arch Therapeutics ($4M, Natick), SQI Diagnostics ($4M, Toronto), Hemostemix ($3M, Blackfalds), and The Green Organic Dutchman Holdings ($3M, Ancaster), alongside multi-billion-dollar transactions from Medtronic and Perrigo. Post-IPO Debt is used across the full spectrum of listed biotech market caps.
Which month in 2022 had the most biotech Post-IPO Debt closes in this dataset?
August 2022 recorded 13 transactions closing between August 2 and August 25, the highest count of any month in these 50 rows. That month included Cerevel Therapeutics ($300M, Boston), ATAI Life Sciences ($175M, Munich), and Opthea ($170M, South Yarra), with activity drawn from US, Canadian, and European issuers. October and July each produced eight closes.
What does the deal size distribution look like below the two largest outliers?
Stripping out Medtronic ($3.5B) and Perrigo ($2.6B), the remaining raises range from $570K to $900M. The upper portion is anchored by Alnylam Pharmaceuticals ($900M), Thermo Fisher Scientific ($741M), Cytokinetics ($450M), and Insmed and Ascendis Pharma (each $500M); the lower-mid band is represented by companies like Theratechnologies ($40M, Montréal), Valeo Pharma ($40M, Kirkland), and Galectin Therapeutics ($60M, Norcross).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.